AXITINIB | AXITINIB | ATC L01XE17
ANTINEOPLASTIC AGENT PROTEIN KINASE INHIBITOR RENAL CELL CARCINOMA | ORAL | Cmax 0.072 MICROMOLAR (5 MILLIGRAM TWICE DAILY) F 58 PERCENT (5 MILLIGRAM) VD 160 LITER (5 MILLIGRAM TWICE DAILY) PPB 99 PERCENT Cl 38 LITER / HOUR HT 4.3 HOUR (5 MILLIGRAM TWICE DAILY) SOLUBILITY IN AQUEOUS MEDIA OVER THE RANGE PH 1.1 TO PH 7.8 IS IN EXCESS OF 0.2 MICROGRAM / MILLILITER | RECEPTOR TYROSINE KINASES VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTORS VEGFR-1 VEGFR-2 VEGFR-3 PDB 4WA9 (THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB) LIGAND CODE = AXI (link to the list of PDB complexes) Download experimental 3D coordinates of AXI with added hydrogens | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR CHEMBL2095227 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR P17948 VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 HOMO SAPIENS ENZYME KINASE PROTEIN KINASE TK VEGFR | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |